Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma Clinical Trial

Official title:

A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00244985
• Other study ID #: CDR0000447130
• Secondary ID: RPC 02-04
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 25, 2005
• Last updated: November 20, 2015
• Start date: September 2005

Study information

• Verified date: November 2015
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with liposomal doxorubicin may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects of giving rituximab together with liposomal doxorubicin and to see how well they work in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Description:

OBJECTIVES:

Primary

• Determine the safety, including qualitative and quantitative toxic effects and their duration and reversibility, of rituximab and doxorubicin HCl liposome in patients with relapsed or refractory, indolent or aggressive CD20-positive B-cell non-Hodgkin's lymphoma.

Secondary

• Determine the efficacy, including overall response rate and durability of objective response, of this regimen in these patients.

• Correlate pretreatment functional, phenotypic, and genotypic characteristics of host immune effector cells with response in patients treated with this regimen.

OUTLINE: This is an open-label, pilot study.

Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 4 years.

PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following indolent or aggressive B-cell non-Hodgkin's lymphoma (NHL) subtypes:

• Grade 1-3 follicular lymphoma

• Mantle cell lymphoma

• Small lymphocytic lymphoma

• Diffuse large B-cell lymphoma

• Diffuse mixed cell lymphoma

• Marginal zone lymphoma

• Relapsed or refractory CD20-positive disease

• Measurable disease

• Must have received = 1 but < 4 prior standard chemotherapy regimens

• No Burkitt's lymphoma or precursor B-lymphoblastic lymphoma

• No CNS lymphoma

PATIENT CHARACTERISTICS:

Performance status

• Karnofsky 60-100%

Life expectancy

• At least 6 months

Hematopoietic

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 75,000/mm^3

• Hemoglobin > 7 g/dL

Hepatic

• AST or ALT < 2 times upper limit of normal (unless due to primary disease)

• Bilirubin = 2 mg/dL

Renal

• Creatinine = 2.0 mg/dL

Cardiovascular

• LVEF = 50% by MUGA and/or 2-D echocardiogram

• No history of New York Heart Association class II-IV cardiac disease

• No congestive heart failure

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No known HIV positivity

• No uncontrolled active bacterial, viral, or fungal infection

• No other serious disease that would preclude study participation

• No other primary malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Recovered from prior immunotherapy

• Prior immunotherapy, including rituximab or other monoclonal antibody, allowed

Chemotherapy

• See Disease Characteristics

• More than 4 weeks since prior chemotherapy and recovered

• No prior doxorubicin (or equivalent anthracycline) at a cumulative dose > 400 mg/m^2

• No other concurrent chemotherapy

Endocrine therapy

• Nonsteroidal hormones for nonlymphoma-related conditions (e.g., insulin for diabetes) allowed

• No concurrent corticosteroids except for a transient inflammatory reaction (i.e., skin rash or hives)

Radiotherapy

• Recovered from prior radiotherapy

• No concurrent radiotherapy

Surgery

• More than 4 weeks since prior major surgery (other than diagnostic surgery) and recovered

Other

• No other concurrent antitumor agents

• No other concurrent investigational agents

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma

Intervention

Biological:
• rituximab
IV

Drug:
• pegylated liposomal doxorubicin hydrochloride
IV

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute	Ortho Biotech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate at 20 weeks		20 weeks	No
Secondary	Partial response rate at 20 weeks		20 weeks	No
Secondary	Overall response rate (complete and partial responses) at 20 weeks		20 weeks	No
Secondary	Time to disease progression at 2 years		2 years	No
Secondary	Survival at 2 years		2 years	No